234 related articles for article (PubMed ID: 32986868)
1. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers.
Litzenburger T; Steffgen J; Benediktus E; Müller F; Schultz A; Klein E; Ramanujam M; Harcken C; Gupta A; Wu J; Wiebe S; Li X; Flack M; Padula SJ; Visvanathan S; Hünnemeyer A; Hui J
Br J Clin Pharmacol; 2021 Apr; 87(4):1824-1838. PubMed ID: 32986868
[TBL] [Abstract][Full Text] [Related]
2. A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single-Dose and Multiple-Rising-Dose Study of the BTK Inhibitor TAK-020 in Healthy Subjects.
Esfandiari E; Chen M; Smithson G; Blair D; Faessel H; Wagner J; Mclean L; Fedyk ER
Clin Transl Sci; 2021 May; 14(3):820-828. PubMed ID: 33650758
[TBL] [Abstract][Full Text] [Related]
3. Safety, pharmacokinetics and pharmacodynamics of branebrutinib (BMS-986195), a covalent, irreversible inhibitor of Bruton's tyrosine kinase: Randomised phase I, placebo-controlled trial in healthy participants.
Catlett IM; Nowak M; Kundu S; Zheng N; Liu A; He B; Girgis IG; Grasela DM
Br J Clin Pharmacol; 2020 Sep; 86(9):1849-1859. PubMed ID: 32198939
[TBL] [Abstract][Full Text] [Related]
4. A phase I trial of PRN1008, a novel reversible covalent inhibitor of Bruton's tyrosine kinase, in healthy volunteers.
Smith PF; Krishnarajah J; Nunn PA; Hill RJ; Karr D; Tam D; Masjedizadeh M; Funk JO; Gourlay SG
Br J Clin Pharmacol; 2017 Nov; 83(11):2367-2376. PubMed ID: 28636208
[TBL] [Abstract][Full Text] [Related]
5. Safety, Tolerability, Pharmacokinetics, Target Occupancy, and Concentration-QT Analysis of the Novel BTK Inhibitor Evobrutinib in Healthy Volunteers.
Becker A; Martin EC; Mitchell DY; Grenningloh R; Bender AT; Laurent J; Mackenzie H; Johne A
Clin Transl Sci; 2020 Mar; 13(2):325-336. PubMed ID: 31654487
[TBL] [Abstract][Full Text] [Related]
6. Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial.
Kaul M; End P; Cabanski M; Schuhler C; Jakab A; Kistowska M; Kinhikar A; Maiolica A; Sinn A; Fuhr R; Cenni B
Clin Transl Sci; 2021 Sep; 14(5):1756-1768. PubMed ID: 33834628
[TBL] [Abstract][Full Text] [Related]
7. Safety, Pharmacokinetics, and Pharmacodynamics in Healthy Volunteers Treated With GDC-0853, a Selective Reversible Bruton's Tyrosine Kinase Inhibitor.
Herman AE; Chinn LW; Kotwal SG; Murray ER; Zhao R; Florero M; Lin A; Moein A; Wang R; Bremer M; Kokubu S; Serone AP; Hanze EL; Viberg A; Morimoto AM; Winter HR; Katsumoto TR
Clin Pharmacol Ther; 2018 Jun; 103(6):1020-1028. PubMed ID: 29484638
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of Bruton's tyrosine kinase inhibitors impairs GPVI-mediated platelet function.
Rigg RA; Aslan JE; Healy LD; Wallisch M; Thierheimer ML; Loren CP; Pang J; Hinds MT; Gruber A; McCarty OJ
Am J Physiol Cell Physiol; 2016 Mar; 310(5):C373-80. PubMed ID: 26659727
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 First-in-Human Pharmacokinetic and Pharmacodynamic Study of JNJ-64264681, a Covalent Inhibitor of Bruton's Tyrosine Kinase.
Leu JH; Miao X; Shalayda K; Coe KJ; Kahnt A; Wu B; Schnarr M; Franks C; Devlin J; Yang TY; Palmer JA; Zhang M; Zhou H; Van Damme W; Smets S; Aguilar Z; Chaplan SR
Clin Pharmacol Drug Dev; 2023 Jun; 12(6):611-624. PubMed ID: 37125450
[TBL] [Abstract][Full Text] [Related]
10. Safety, pharmacokinetics, and pharmacodynamics of BMS-986142, a novel reversible BTK inhibitor, in healthy participants.
Lee SK; Xing J; Catlett IM; Adamczyk R; Griffies A; Liu A; Murthy B; Nowak M
Eur J Clin Pharmacol; 2017 Jun; 73(6):689-698. PubMed ID: 28265691
[TBL] [Abstract][Full Text] [Related]
11. BTK inhibition ameliorates kidney disease in spontaneous lupus nephritis.
Chalmers SA; Glynn E; Garcia SJ; Panzenbeck M; Pelletier J; Dimock J; Seccareccia E; Bosanac T; Khalil S; Harcken C; Webb D; Nabozny G; Fine JS; Souza D; Klein E; Herlitz L; Ramanujam M; Putterman C
Clin Immunol; 2018 Dec; 197():205-218. PubMed ID: 30339790
[TBL] [Abstract][Full Text] [Related]
12. Target Occupancy and Functional Inhibition of JAK3 and TEC Family Kinases by Ritlecitinib in Healthy Adults: An Open-Label, Phase 1 Study.
Martin DA; Telliez JB; Pleasic-Williams S; Zhang Y; Tierney B; Blatnik M; Gale JD; Banfield C; Zhou Y; Lejeune A; Zwillich SH; Stevens E; Tiwari N; Kieras E; Karanam A
J Clin Pharmacol; 2024 Jan; 64(1):67-79. PubMed ID: 37691236
[TBL] [Abstract][Full Text] [Related]
13. Highly selective inhibition of Bruton's tyrosine kinase attenuates skin and brain disease in murine lupus.
Chalmers SA; Wen J; Doerner J; Stock A; Cuda CM; Makinde HM; Perlman H; Bosanac T; Webb D; Nabozny G; Fine JS; Klein E; Ramanujam M; Putterman C
Arthritis Res Ther; 2018 Jan; 20(1):10. PubMed ID: 29370834
[TBL] [Abstract][Full Text] [Related]
14. Bruton's Tyrosine Kinase Inhibitors Impair FcγRIIA-Driven Platelet Responses to Bacteria in Chronic Lymphocytic Leukemia.
Naylor-Adamson L; Chacko AR; Booth Z; Caserta S; Jarvis J; Khan S; Hart SP; Rivero F; Allsup DJ; Arman M
Front Immunol; 2021; 12():766272. PubMed ID: 34912339
[TBL] [Abstract][Full Text] [Related]
15. Safety, pharmacokinetics and pharmacodynamics of HWH486 capsules in healthy adults: A randomized, double-blind, placebo-controlled, phase I dose-escalation study.
Chen M; Du S; Cheng Y; Zhu X; Wang Y; Shu S; Men Y; He M; Wang H; He Z; Cai L; Zhu J; Wu Z; Li Y; Feng P
Int Immunopharmacol; 2024 Jan; 126():111285. PubMed ID: 38061118
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168).
Owens TD; Smith PF; Redfern A; Xing Y; Shu J; Karr DE; Hartmann S; Francesco MR; Langrish CL; Nunn PA; Gourlay SG
Clin Transl Sci; 2022 Feb; 15(2):442-450. PubMed ID: 34724345
[TBL] [Abstract][Full Text] [Related]
17. Discovery of JNJ-64264681: A Potent and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Tichenor MS; Wiener JJM; Rao NL; Bacani GM; Wei J; Pooley Deckhut C; Barbay JK; Kreutter KD; Chang L; Clancy KW; Murrey HE; Wang W; Ahn K; Huber M; Rex E; Coe KJ; Wu J; Rui H; Sepassi K; Gaudiano M; Bekkers M; Cornelissen I; Packman K; Seierstad M; Xiouras C; Bembenek SD; Alexander R; Milligan C; Balasubramanian S; Lebsack AD; Venable JD; Philippar U; Edwards JP; Hirst G
J Med Chem; 2022 Nov; 65(21):14326-14336. PubMed ID: 36314537
[TBL] [Abstract][Full Text] [Related]
18. ABBV-105, a selective and irreversible inhibitor of Bruton's tyrosine kinase, is efficacious in multiple preclinical models of inflammation.
Goess C; Harris CM; Murdock S; McCarthy RW; Sampson E; Twomey R; Mathieu S; Mario R; Perham M; Goedken ER; Long AJ
Mod Rheumatol; 2019 May; 29(3):510-522. PubMed ID: 29862859
[TBL] [Abstract][Full Text] [Related]
19. BTK inhibition modulates multiple immune cell populations involved in the pathogenesis of immune mediated nephritis.
Chalmers SA; Garcia SJ; Webb D; Herlitz L; Fine J; Klein E; Ramanujam M; Putterman C
Clin Immunol; 2021 Feb; 223():108640. PubMed ID: 33296718
[TBL] [Abstract][Full Text] [Related]
20. Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.
Byun JY; Koh YT; Jang SY; Witcher JW; Chan JR; Pustilnik A; Daniels MJ; Kim YH; Suh KH; Linnik MD; Lee YM
Sci Rep; 2021 Sep; 11(1):18671. PubMed ID: 34548595
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
